Amendment: Large owner Polaris Management Co. Vii, L.L.C. converted options into 1,715,972 shares and bought $9,999,990 worth of shares (909,090 units at $11.00) (SEC Form 4)

$CAMP
Get the next $CAMP alert in real time by email
SEC FORM 4/A SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Polaris Management Co. VII, L.L.C.

(Last) (First) (Middle)
ONE MARINA PARK DRIVE, 8TH FLOOR

(Street)
BOSTON MA 02210

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
10/15/2024
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2024 C(1) 1,250,061 A (1) 1,250,061 I See footnote(2)
Common Stock 10/15/2024 C(1) 87,448 A (1) 87,448 I See footnote(3)
Common Stock 10/15/2024 C(4) 353,718 A (4) 1,603,779 I See footnote(2)
Common Stock 10/15/2024 C(4) 24,745 A (4) 112,193 I See footnote(3)
Common Stock 10/15/2024 P 909,090 A $11 909,090 I See footnote(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Prime Preferred Stock (1) 10/15/2024 C 14,020,475 (1) (1) Common Stock 1,250,061 (1) 0 I See Footnote(2)
Series A Prime Preferred Stock (1) 10/15/2024 C 980,829 (1) (1) Common Stock 87,448 (1) 0 I See Footnote(3)
Series B Preferred Stock (4) 10/15/2024 C 3,967,234 (4) (4) Common Stock 353,718 (4) 0 I See Footnote(2)
Series B Preferred Stock (4) 10/15/2024 C 277,536 (4) (4) Common Stock 24,745 (4) 0 I See Footnote(3)
1. Name and Address of Reporting Person*
Polaris Management Co. VII, L.L.C.

(Last) (First) (Middle)
ONE MARINA PARK DRIVE, 8TH FLOOR

(Street)
BOSTON MA 02210

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Polaris Partners VII, L.P.

(Last) (First) (Middle)
ONE MARINA PARK DRIVE, 8TH FLOOR

(Street)
BOSTON MA 02210

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Polaris Entrepreneurs' Fund VII, L.P.

(Last) (First) (Middle)
ONE MARINA PARK DRIVE
8TH FLOOR

(Street)
BOSTON MA 02210

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Polaris Partners X, L.P.

(Last) (First) (Middle)
ONE MARINA PARK DRIVE, 8TH FLOOR

(Street)
BOSTON MA 02210

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Polaris Partners GP X, L.L.C.

(Last) (First) (Middle)
ONE MARINA PARK DRIVE, 8TH FLOOR

(Street)
BOSTON MA 02210

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
SCHULMAN AMY W

(Last) (First) (Middle)
ONE MARINA PARK DRIVE, 8TH FLOOR

(Street)
BOSTON MA 02210

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Chee Brian

(Last) (First) (Middle)
ONE MARINA PARK DRIVE, 8TH FLOOR

(Street)
BOSTON MA 02210

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
2. The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
3. The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
4. On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
5. The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Remarks:
This Form 4/A amends the Form 4 filing dated October 15, 2024 (the "Original Form 4") solely to add Brian Chee as an additional Reporting Person. Although Mr. Chee was disclosed in the Original Form 4, he was not included as a Reporting Person because he did not have codes for the EDGAR system at such time.
/s/ Lauren Crockett, as attorney-in-fact for Polaris Management Co. VII, L.L.C., general partner of Polaris Partners VII, L.P. 10/22/2024
/s/ Lauren Crockett, as attorney-in-fact for Polaris Management Co. VII, L.L.C. 10/22/2024
/s/ Lauren Crockett, as attorney-in-fact for Polaris Management Co. VII, L.L.C., general partner of Polaris Entrepreneurs' Fund VII, L.P. 10/22/2024
/s/ Lauren Crockett, as general counsel of Polaris Partners GP X, L.L.C., general partner of Polaris Partners X, L.P. 10/22/2024
/s/ Lauren Crockett, as general counsel of Polaris Partners GP X, L.L.C. 10/22/2024
/s/ Lauren Crockett, as attorney-in-fact for Brian Chee 10/22/2024
/s/ Lauren Crockett, as attorney-in-fact for Amy Schulman 10/22/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $CAMP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CAMP

DatePrice TargetRatingAnalyst
11/5/2024Outperform
William Blair
11/5/2024$18.00Overweight
Piper Sandler
11/5/2024$23.00Overweight
JP Morgan
8/16/2022$8.00 → $10.00Hold → Buy
Craig Hallum
12/22/2021$15.00 → $14.00Buy
Canaccord Genuity
12/22/2021$14.00 → $10.00Buy → Hold
Craig-Hallum
9/24/2021$16.00 → $14.00Buy
Craig Hallum
6/25/2021$19.00 → $18.50Buy
Roth Capital
More analyst ratings

$CAMP
Press Releases

Fastest customizable press release news feed in the world

See more
  • CAMP4 to Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will participate in the following upcoming investor conferences: Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFormat:   Corporate PresentationDate and Time:  February 12, 2025, 10:00 a.m. ESTLocation:  VirtualWebcast Link:  Click Here    Leerink Partners Global Healthcare ConferenceFormat:  Fireside ChatDate and Time:  March 1

  • CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California, on Wednesday, January 15, 2025, at 3:45 p.m. PST. The event will be webcast live and can be accessed on the investor relations page of CAMP4's website at www.investors.camp4tx.com. A replay of the webcast will be archived on the C

  • CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

    Data from Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 for the treatment of urea cycle disorders (UCDs) demonstrates favorable safety resultsCompleted dosing in the first two Multiple Ascending Dose (MAD) cohorts, and initiated dosing in Cohort 3MAD safety and key study biomarker data expected in 2H 2025CAMP4 added to Russell 2000® IndexInitiation of new discovery program targeting a GBA1 regRNA for the treatment of Parkinson's disease (PD)Company to present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15 at 3:45 p.m. PST CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinic

$CAMP
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CAMP
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$CAMP
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CAMP
SEC Filings

See more

$CAMP
Leadership Updates

Live Leadership Updates

See more
  • CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

    CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

    $CAMP
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CalAmp Appoints Chris Adams as President and Chief Executive Officer

    IRVINE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, is pleased to announce that Chris Adams will be joining the company as President and Chief Executive Officer (CEO), effective January 22, 2024. Adams is an accomplished technology leader who brings a wealth of knowledge and experience to CalAmp. He possesses a unique combination of technical depth, operational skills, and general management experience from a broad range of technology companies – most recently as VP/GM of the Automotive Sensing Division at onsemi. "After a comprehensiv

  • CalAmp Announces CEO Transition

    IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with a data-driven solutions ecosystem, today announced that Jeff Gardner will be stepping down from his role as Chief Executive Officer, effective no later than October 30, 2023. The Company has commenced a search for its next CEO and will be retaining an executive search firm. In announcing his departure, Jeff Gardner shared, "It has been a privilege working with the amazing group of colleagues at CalAmp. I am proud of all that we have accomplished and the progress we have made in positioning the Company for growth and p

$CAMP
Financials

Live finance-specific insights

See more
  • CalAmp Reports Third Quarter Fiscal Year 2024 Financial Results

    IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2024 ended November 30, 2023. Third Quarter Fiscal Year 2024 Financial Overview    Revenue was $53.6 million, representing a 13% decline QoQ and a 32% decline YoY driven primarily by softer demand in the TSP market segment.Gross margin was 33%, representing a decline of approximately 340 bps QoQ and 100 bps decline YoY as a result of a shift in product mix and a higher-than-normal reserve for excess and obsolete inventory.S&SS revenue was $34.5

  • CalAmp Announces Date for Fiscal 2024 Third Quarter Earnings Conference Call

    IRVINE, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 third quarter financial results after market close on Tuesday, January 9, 2024. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on January 9, 2024, to discuss its financial results. The call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at CalAmp IR Web Site. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A repla

  • CalAmp Announces Completion of Strategic Financing with Lynrock Lake

    IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, today announced the closing of a $45 million strategic financing with Lynrock Lake Master Fund LP ("Lynrock") in the form of a term loan maturing in November 2027. Lynrock is an existing holder of a large majority of CalAmp's 2.00% Convertible Senior Notes maturing in August 2025 (the "Notes"). In connection with the execution of the term loan agreement, CalAmp is amending the Notes to add a security interest. "As a long-standing investor in CalAmp, we are pleased to provide the company with add

$CAMP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more